STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

As Cytek Biosciences navigates its regulatory quiet period, the investment community is looking ahead to the imminent release of its complete fourth-quarter and ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

Quest Diagnostics has introduced a new flow cytometry MRD blood test for myeloma, a cancer arising from abnormal plasma cells.

The review emphasizes that differing CLSI and EUCAST breakpoints complicate AMR tracking, calling for standardized criteria ...

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for manufacturing that provide secure, real-time access to data, which can help ...

Flow cytometry is a key diagnostic technique in hematology that provides protein information at a single-cell level. Traditionally interpreted manually in a sequence of two-dimensional plots, ...